Dexcom Inc Q3 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Congrats on an absolutely fantastic quarter. There is a lot to talk about here, but just keeping it to one question. What really showed just so much upside was the U.S. number this quarter, along with the profitability. So question really is, one, how much of that do we ascribe to the new basal indication with growth from both Medicare and commercial patients? And we started to see this in France and Japan, and I hear that a lot of European countries might over the course of '24 start covering for Basal. So the question is really how much is Basal contributing today? And how big can it be over the coming years if all of Europe starts to bring on enhanced reimbursement something that would have been unimaginable just 12 months ago?

Question: Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst : I will also say congrats on a really great quarter. I was just curious. So Jereme, you alluded to the fact that BaChampionl seems to be starting to ramp similar to how the insulin-intensive type 2 did when you got coverage there. What about from a utilization perspective? Any color you can give on how these basal patients are adopting technology? Is it similar to what you saw in the mobile study? I know it's early, but we should have had some reorders by now. So just curious what you're seeing.

Question: Mathew Justin Blackman - Stifel, Nicolaus & Company, Incorporated, Research Division - Analyst : So we did a big CGM survey last month. And one of the most interesting takeaways were very positive early expectations for the non-insulin opportunity. The docs expect to peak penetration over time to approach the 50-plus percent range and with a pretty steep curve. So really does seem somewhat similar to the type 2 intensive rollout. Just hoping for any color on how that tracks versus your expectations for non-insulin assuming some reimbursement over time? Just any color there would be helpful.